Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Inclusion Criteria:

Measurable disease of MM as defined by at least ONE of the following:

Serum monoclonal protein (SPEP) ≥1 g/dL
Urine M-protein ≥200 mg/24 hrs
Serum free light chain (SFLC): involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal kappa to lambda serum free light chain ratio
Relapsed or relapsed and refractory MM after receiving at least 2 previous therapies, including an immunomodulator and bortezomib and had either no response or documented disease progression (according to IMWG criteria) to the most recent treatment regimen
Adequate hematologic, hepatic, and renal function
ECOG performance status of 0-2

Inclusion Criteria for Phase 2 Sub-study Cohort:

Must meet all inclusion criteria defined in main study and in addition the following criteria must be met:

Subject must have received a regimen containing carfilzomib in combination with dexamethasone as their most recent line of therapy and have:

Achieved less than a partial response (
OR

Disease progression following an initial confirmed response of MR or better to the combination (according to IMWG response criteria).

Exclusion Criteria:

Subject must not have primary refractory disease
Plasma cell leukemia, primary amyloidosis or POEMS syndrome
Unable to swallow capsules or disease significantly affecting gastrointestinal function
Requires anti-coagulation with warfarin or a vitamin K antagonist
Requires treatment with strong CYP3A inhibitors

Exclusion Criteria for Phase 2 Sub-study Cohort:

Must not meet any exclusion criteria defined in main study except for exclusion criteria "Subject must not have primary refractory disease" which is related to prior carfilzomib